Type
|
Corporation |
---|---|
Traded as | NASDAQ: VRTX NASDAQ-100 Component S&P 500 Component |
Industry | Pharmaceuticals & Biotherapeutics) |
Founded | 1989 |
Headquarters | Boston, Massachusetts |
Key people
|
|
Products | Product Pipeline] |
Revenue | US$1.4 billion (2011) |
Website | www.vrtx.com |
Vertex Pharmaceuticals is an American Pharmaceutical company based in Boston, Massachusetts.
Vertex was founded in 1989 by Joshua Boger and Kevin J. Kinsella. Vertex was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
By 2004, its product pipeline focused on viral infections, inflammatory and autoimmune disorders, and cancer. It maintains headquarters in South Boston, Massachusetts, and two research facilities, in San Diego, California, and Oxford, England. The company's beginnings were profiled by Barry Werth in the 1994 book The Billion-Dollar Molecule and its further development in his 2014 book, The Antidote: Inside the World of New Pharma. In 2009, the company had about 1,800 employees, including 1,200 in the Boston area.
In January 2014, Vertex completed its move from Cambridge, Massachusetts to Boston, Massachusetts, and took residence in a new, $800 million complex. Located on the South Boston waterfront, it will mark the first time in the company's history that all of the roughly 1,200 Vertex employees in the Greater Boston area will be working together.
Since late 2011, when Jeffrey M. Leiden joined Vertex as CEO, Vertex has ranked among the top 15 best performing companies on the Standard & Poor’s 500. Vertex shares increased 250 percent in the same period. Vertex posted only one annual profit since it was founded in 1989.
In May 2011, the Food and Drug Administration (FDA) approved the drug telaprevir (Incivek), an oral treatment for hepatitis C marketed by Vertex. Development and commercialization of telaprevir is shared with Johnson & Johnson for European distribution and Mitsubishi for Asia. Telaprevir is a protease inhibitor.
In 2012 ivacaftor, was designated as an orphan drug, identifying cystic fibrosis as affecting fewer than 200,000 people in the United States. On January 31, 2012, Vertex gained FDA approval of the first drug, Kalydeco, to treat the underlying cause of cystic fibrosis rather than the symptoms, in patients 6 years or older who have the G551D gene mutation. In the US, 30,000 people have cystic fibrosis. About 4% of those, or 1,200, have the G551D gene mutation. Vertex is marketing the drug at $307,000 a year per patient. Vertex also is studying ivacaftor in combination with another drug (lumacaftor) for the most common mutation in CF, known as F508del, and expects the first set of results in 2012. Vertex worked for 13 years with the Cystic Fibrosis Foundation to develop the drug.
In the UK, the company provided the drug free for a limited time for certain patients, then left the hospitals to decide whether to continue to pay for it for those patients. UK agencies estimated the cost per quality adjusted life year (QALY) at between £335,000 and £1,274,000—far above the NICE thresholds of £20,000-£30,000.
On November 5, 2014 Vertex announced the submission of a New Drug Application (NDA) to the FDA for a fully co-formulated combination of lumacaftor and ivacaftor for people with cystic fibrosis ages 12 and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. In 2015, FDA approved Orkambi lumacaftor/ivacaftor to treat cystic fibrosis (CF) in patients 12 years and older, who have the F508del mutation.
In 2016, the company entered into a collaboration with Moderna, in fact taking an ownership stake in the company, to develop new mRNA-based therapeutics to treat CF.
In the late 1990s the Bethesda-based Cystic Fibrosis Foundation, encouraged by then-President Robert Beall, began investing in Vertex— when it was a small start-up biotechnology company— to help fund the development of Kalydeco in the form of venture philanthropy. The total investment amounted to $150 million. In 2014, the CF Foundation sold the rights to the royalties of the drugs for $3.3 billion, twenty times the Foundation’s 2013 budget.
By 2015 the annual cost of Kalydeco had risen to more than $300,000 per patient.
According to an article published in the Milwaukee Journal Sentinel Vertex executives "grossed more than $100 million by cashing in stocks and stock options" and at "one point, the value of company's stock increased more $6 billion in a single day."
Twenty-nine physicians and scientists working with people with cystic fibrosis (CF) wrote to Jeff Leiden, CEO of Vertex Pharmaceuticals to plead for lower prices.
"We are aware of the financial complexities of the huge expenses for R & D with respect to the small number of patients or the market system that enables these advances to become reality. Yet -- notwithstanding all your patient support programs -- it is at best unseemly for Vertex to charge our patients’ insurance plans (including strapped state medical assistance plans), $294,000 annually for two pills a day (a 10-fold increase in a typical patient's total drug costs). This action could appear to be leveraging pain and suffering into huge financial gain for speculators, some of whom were your top executives who reportedly made millions of dollars in a single day (Boston Globe, May 29)."
The company responded in an email that "while publicly funded academic research provided important early understanding of the cause of cystic fibrosis, it took Vertex scientists 14 years of their own research, funded mostly by the company, before the drug won approval."
On April 15, 2015 in Cambridge, MA, Joan Finnegan Brooks of the Cystic Fibrosis Foundation, spoke about the role of Vertex and venture philanthropy to a panel of biotech leaders hosted by Life Sciences Foundation on the topic of patient advocacy in the biotech industry. While Brooks, who has Cystic Fibrosis, expressed gratitude for Vertex' development of Kalydeco, she observed that 25% of Cystic Fibrosis patients are not getting the medical care they need because of the prohibitive cost of the drug.
Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q3 2022 | 2022-10-31 | Future report Set alerts | |
Q2 2022 | 2022-08-04 | 3.60 | 3.60 |
Q1 2022 | 2022-05-05 | 3.52 | 3.52 |
Q4 2021 | 2022-01-26 | 3.37 | 3.37 |
Q3 2021 | 2021-11-02 | 3.56 | 3.56 |
Q2 2021 | 2021-07-29 | 3.11 | 3.11 |
Q1 2021 | 2021-04-29 | 2.98 | 2.98 |
Q4 2020 | 2021-02-01 | 2.51 | 2.51 |
Q3 2020 | 2020-10-29 | 2.64 | 2.64 |
Q2 2020 | 2020-07-30 | 2.61 | 2.61 |
2016-07-07 | Reiterated Rating | Maxim Group | Hold | |
2016-06-18 | Reiterated Rating | Piper Jaffray | Buy | |
2016-06-18 | Reiterated Rating | Piper Jaffray Cos. | Buy | |
2016-06-17 | Reiterated Rating | Jefferies Group | Buy | $103.00 |
2016-06-16 | Reiterated Rating | Credit Suisse | Buy | |
2016-06-16 | Reiterated Rating | Credit Suisse Group AG | Buy | |
2016-05-31 | Reiterated Rating | Jefferies Group | Buy | |
2016-05-12 | Reiterated Rating | Morgan Stanley | Buy | |
2016-05-01 | Reiterated Rating | Robert W. Baird | Outperform | $144.00 to $128.00 |
2016-04-28 | Lower Price Target | Barclays | Overweight | $135.00 to $110.00 |
2016-04-28 | Downgrade | Goldman Sachs | Buy to Neutral | $109.00 to $88.00 |
2016-04-28 | Lower Price Target | RBC Capital | Outperform | $135.00 to $115.00 |
2016-04-28 | Reiterated Rating | Leerink Swann | Buy | |
2016-04-28 | Reiterated Rating | Needham & Company LLC | Hold | |
2016-04-28 | Reiterated Rating | HC Wainwright | Buy | $155.00 |
2016-04-28 | Reiterated Rating | Maxim Group | Hold | |
2016-04-28 | Downgrade | Goldman Sachs Group Inc. | Buy to Neutral | $109.00 to $88.00 |
2016-04-28 | Lower Price Target | Barclays PLC | Overweight | $135.00 to $110.00 |
2016-04-28 | Lower Price Target | Royal Bank Of Canada | Outperform | $135.00 to $115.00 |
2016-04-25 | Reiterated Rating | Robert W. Baird | Buy | |
2016-04-17 | Reiterated Rating | Cowen and Company | Hold | |
2016-04-11 | Lower Price Target | Credit Suisse | Outperform | $143.00 to $112.00 |
2016-04-10 | Reiterated Rating | Leerink Swann | Outperform | |
2016-04-07 | Initiated Coverage | BMO Capital Markets | Market Perform | $90.00 |
2016-04-06 | Lower Price Target | Jefferies Group | Buy | $108.00 |
2016-04-04 | Reiterated Rating | JPMorgan Chase & Co. | Buy | |
2016-04-01 | Lower Price Target | Stifel Nicolaus | Buy | $140.00 to $108.00 |
2016-03-28 | Lower Price Target | Guggenheim | Buy | $145.00 to $114.00 |
2016-03-27 | Reiterated Rating | Jefferies Group | Buy | $116.00 |
2016-03-23 | Reiterated Rating | Piper Jaffray | Buy | |
2016-03-23 | Lower Price Target | Goldman Sachs | Buy | $129.00 to $106.00 |
2016-03-19 | Reiterated Rating | RBC Capital | Buy | |
2016-03-18 | Lower Price Target | RBC Capital | Outperform | $145.00 to $135.00 |
2016-03-15 | Reiterated Rating | Bank of America | Neutral | $108.00 |
2016-03-15 | Reiterated Rating | Bank of America Corp. | Neutral | $108.00 |
2016-03-14 | Reiterated Rating | Leerink Swann | Outperform | $128.00 |
2016-03-11 | Reiterated Rating | Piper Jaffray | Overweight | $131.00 |
2016-03-10 | Reiterated Rating | Maxim Group | Hold | |
2016-03-08 | Reiterated Rating | Leerink Swann | Outperform | $131.00 to $128.00 |
2016-03-08 | Reiterated Rating | Cowen and Company | Market Perform | $95.00 |
2016-02-22 | Lower Price Target | Goldman Sachs | $135.00 to $129.00 | |
2016-02-11 | Initiated Coverage | Oppenheimer | Market Perform | |
2016-02-11 | Initiated Coverage | Oppenheimer Holdings Inc. | Market Perform | |
2016-02-08 | Reiterated Rating | Cowen and Company | Market Perform | $95.00 |
2016-02-08 | Reiterated Rating | Maxim Group | Hold | |
2016-02-06 | Reiterated Rating | Leerink Swann | Buy | |
2016-02-04 | Initiated Coverage | Leerink Swann | Outperform | $131.00 |
2016-02-04 | Lower Price Target | Argus | Buy | $154.00 to $140.00 |
2016-02-03 | Reiterated Rating | HC Wainwright | Buy | $155.00 |
2016-02-01 | Upgrade | Jefferies Group | Hold to Buy | $142.00 to $120.00 |
2016-01-30 | Reiterated Rating | Piper Jaffray | Overweight | $180.00 to $143.00 |
2016-01-28 | Lower Price Target | Barclays | Overweight | $150.00 to $135.00 |
2016-01-28 | Reiterated Rating | Needham & Company LLC | Hold | |
2016-01-28 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $147.00 |
2016-01-26 | Reiterated Rating | Stifel Nicolaus | Buy | $160.00 |
2016-01-19 | Initiated Coverage | Credit Suisse | Outperform | $151.00 |
2016-01-19 | Reiterated Rating | Maxim Group | Hold | |
2016-01-13 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $153.00 |
2016-01-12 | Reiterated Rating | Needham & Company LLC | Hold | |
2016-01-11 | Reiterated Rating | Cowen and Company | Market Perform | $110.00 |
2016-01-05 | Reiterated Rating | Piper Jaffray | Overweight | $180.00 |
2015-12-01 | Initiated Coverage | Stifel Nicolaus | Buy | $160.00 to $160.00 |
2015-11-26 | Upgrade | JPMorgan Chase & Co. | Neutral to Outperform | |
2015-11-10 | Reiterated Rating | Piper Jaffray | Buy | |
2015-11-05 | Reiterated Rating | Guggenheim | Buy | |
2015-10-30 | Upgrade | HC Wainwright | Neutral to Buy | $85.00 to $155.00 |
2015-10-29 | Reiterated Rating | Piper Jaffray | Buy | $163.00 to $180.00 |
2015-10-29 | Reiterated Rating | Needham & Company LLC | Hold | |
2015-10-29 | Boost Price Target | Morgan Stanley | $152.00 | |
2015-10-29 | Boost Price Target | JPMorgan Chase & Co. | $153.00 | |
2015-10-27 | Reiterated Rating | Oppenheimer | Hold | |
2015-10-27 | Reiterated Rating | Robert W. Baird | Buy | $160.00 |
2015-10-27 | Reiterated Rating | William Blair | Buy | $158.00 |
2015-10-26 | Lower Price Target | JMP Securities | Market Outperform | $140.00 |
2015-10-25 | Reiterated Rating | RBC Capital | Buy | $145.00 |
2015-10-20 | Reiterated Rating | Oppenheimer | Market Perform | |
2015-10-14 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $146.00 |
2015-10-14 | Reiterated Rating | Needham & Company LLC | Hold | |
2015-10-12 | Reiterated Rating | RBC Capital | Buy | $145.00 |
2015-10-02 | Upgrade | Morgan Stanley | Equal Weight to Overweight | $118.00 to $148.00 |
2015-09-28 | Upgrade | Argus | Hold to Buy | $103.28 to $126.00 |
2015-09-23 | Reiterated Rating | RBC Capital | Buy | $145.00 |
2015-09-22 | Reiterated Rating | Piper Jaffray | Buy | $163.00 |
2015-09-15 | Reiterated Rating | Piper Jaffray | Buy | |
2015-09-15 | Initiated Coverage | Nomura | Buy | $162.00 |
2015-09-15 | Initiated Coverage | Nomura Holdings Inc. | Buy | $162.00 |
2015-09-14 | Upgrade | Barclays | Equal Weight to Overweight | $120.00 to $150.00 |
2015-09-08 | Initiated Coverage | Jefferies Group | Hold | $130.00 |
2015-07-31 | Reiterated Rating | Deutsche Bank | Buy | $155.00 |
2015-07-31 | Reiterated Rating | Deutsche Bank AG | Buy | $155.00 |
2015-07-30 | Reiterated Rating | JMP Securities | Buy | $145.00 to $148.00 |
2015-07-30 | Reiterated Rating | Needham & Company LLC | Hold | |
2015-07-29 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | |
2015-07-24 | Reiterated Rating | HC Wainwright | Neutral | $85.00 |
2015-07-07 | Boost Price Target | William Blair | Outperform | $138.00 to $158.00 |
2015-07-07 | Lower Price Target | Morgan Stanley | $120.00 to $119.00 | |
2015-07-07 | Lower Price Target | JMP Securities | Market Outperform | $152.00 to $145.00 |
2015-07-07 | Lower Price Target | BTIG Research | Buy | $200.00 to $180.00 |
2015-07-06 | Reiterated Rating | HC Wainwright | Hold | $85.00 |
2015-07-06 | Reiterated Rating | Piper Jaffray | Overweight | $146.00 to $161.00 |
2015-07-06 | Reiterated Rating | Leerink Swann | Outperform | $150.00 to $158.00 |
2015-07-06 | Boost Price Target | Bank of America | Neutral | $130.00 to $133.00 |
2015-07-06 | Boost Price Target | Robert W. Baird | Buy | $131.00 to $160.00 |
2015-07-03 | Reiterated Rating | Goldman Sachs | Buy | $142.00 |
2015-06-23 | Boost Price Target | RBC Capital | Outperform | $130.00 to $145.00 |
2015-06-09 | Reiterated Rating | JMP Securities | Outperform | $152.00 |
2015-06-05 | Reiterated Rating | Canaccord Genuity | Buy | $150.00 |
2015-05-14 | Reiterated Rating | Canaccord Genuity | Buy | $150.00 |
2015-05-14 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | |
2015-05-14 | Reiterated Rating | HC Wainwright | Neutral | $85.00 |
2015-05-13 | Reiterated Rating | Needham & Company LLC | Hold | |
2015-05-08 | Set Price Target | RBC Capital | Buy | $130.00 |
2015-05-08 | Reiterated Rating | Robert W. Baird | Positive | $131.00 |
2015-05-07 | Reiterated Rating | William Blair | Outperform | $126.00 to $138.00 |
2015-05-03 | Reiterated Rating | Canaccord Genuity | Buy | $150.00 |
2015-04-30 | Reiterated Rating | Needham & Company LLC | Hold | |
2015-04-30 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $130.00 to $138.00 |
2015-04-30 | Boost Price Target | Citigroup Inc. | Buy | $141.00 to $156.00 |
2015-04-30 | Boost Price Target | Leerink Swann | Outperform | $131.00 to $150.00 |
2015-04-27 | Initiated Coverage | Oppenheimer | Market Perform | |
2015-04-10 | Initiated Coverage | Canaccord Genuity | Buy | $150.00 |
2015-03-23 | Set Price Target | Deutsche Bank | Buy | $155.00 |
2015-03-11 | Reiterated Rating | BTIG Research | Buy | $200.00 |
2015-01-29 | Boost Price Target | Credit Suisse | Buy | $129.00 to $155.00 |
2015-01-29 | Boost Price Target | Deutsche Bank | Buy | $129.00 to $155.00 |
2015-01-29 | Downgrade | Maxim Group | Buy to Hold | $148.00 to $121.00 |
2015-01-29 | Downgrade | Needham & Company LLC | Buy to Hold | |
2015-01-13 | Reiterated Rating | Citigroup Inc. | Buy | $136.00 to $141.00 |
2015-01-09 | Initiated Coverage | Janney Montgomery Scott | Neutral | $126.00 |
2015-01-06 | Initiated Coverage | Barclays | Equal Weight | $120.00 |
2015-01-06 | Initiated Coverage | BTIG Research | Buy | $200.00 |
2015-01-05 | Set Price Target | JPMorgan Chase & Co. | Buy | $130.00 |
2014-12-30 | Reiterated Rating | RBC Capital | Positive | |
2014-12-01 | Boost Price Target | Maxim Group | Buy | $122.00 to $148.00 |
2014-11-06 | Initiated | CRT Capital | Buy | $175 |
2014-11-05 | Initiated Coverage | CRT Capital | Buy | $175.00 |
2014-10-29 | Reiterated Rating | JMP Securities | Market Outperform | $115.00 to $133.00 |
2014-10-29 | Boost Price Target | RBC Capital | Outperform | $120.00 to $130.00 |
2014-10-13 | Upgrade | Wells Fargo & Co. | Neutral to Outperform | $129.00 to $125.00 |
2014-10-13 | Upgrade | Piper Jaffray | Neutral to Overweight | $87.50 to $125.00 |
2014-10-13 | Upgrade | Wells Fargo | Neutral to Outperform | $129.00 to $125.00 |
2014-10-10 | Reiterated Rating | Deutsche Bank | Buy | $127.00 |
2014-10-10 | Boost Price Target | Maxim Group | Buy | $109.00 to $117.00 |
2014-10-09 | Reiterated Rating | RBC Capital | Outperform | $120.00 |
2014-10-02 | Initiated Coverage | Guggenheim | Buy | $147.00 |
2014-09-17 | Reiterated | Deutsche Bank | Buy | $103 to $127 |
2014-09-16 | Boost Price Target | Deutsche Bank | Buy | $103.00 to $127.00 |
2014-09-10 | Reiterated Rating | RBC Capital | Outperform | $120.00 |
2014-09-05 | Upgrade | Goldman Sachs | Neutral to Buy | $109.00 to $131.00 |
2014-07-07 | Downgrade | Oppenheimer | Outperform to Market Perform | |
2014-06-25 | Reiterated | Needham | Buy | $95 to $115 |
2014-06-25 | Downgrade | H.C. Wainwright | Buy to Neutral | $105 to $85 |
2014-06-25 | Boost Price Target | Goldman Sachs | $109.00 | |
2014-06-25 | Reiterated Rating | Citigroup Inc. | Buy | $103.00 to $136.00 |
2014-06-25 | Boost Price Target | Sanford C. Bernstein | $65.00 to $107.00 | |
2014-06-25 | Boost Price Target | Leerink Swann | Outperform | $100.00 to $125.00 |
2014-06-25 | Downgrade | HC Wainwright | Buy to Neutral | $105.00 to $85.00 |
2014-06-24 | Boost Price Target | Maxim Group | Buy | $92.00 to $107.00 |
2014-06-24 | Boost Price Target | Needham & Company LLC | Positive to Buy | $95.00 to $115.00 |
2014-06-24 | Reiterated Rating | Deutsche Bank | Buy | |
2014-06-05 | Reiterated Rating | HC Wainwright | Buy | |
2014-04-21 | Upgrade | Ned Davis Research | Sell to Neutral | |
2014-02-24 | Boost Price Target | Maxim Group | Buy | $88.00 to $92.00 |
2013-10-31 | Downgrade | Sanford C. Bernstein | Outperform to Market Perform | |
2013-10-30 | Downgrade | Summer Street Research | Buy to Neutral | |
2013-10-30 | Lower Price Target | Credit Suisse | Neutral | $80.00 to $78.00 |
2013-10-30 | Downgrade | Summer Street | Buy to Neutral | |
2013-10-29 | Reiterated Rating | Needham & Company LLC | Buy | $95.00 |
2013-10-29 | Lower Price Target | Cowen and Company | Neutral | $87.94 to $80.00 |
2013-10-29 | Reiterated Rating | Wells Fargo & Co. | Outperform | |
2013-10-29 | Reiterated Rating | Wells Fargo | Outperform | |
2013-10-21 | Reiterated Rating | Needham & Company LLC | Buy | $95.00 |
2013-10-16 | Lower Price Target | Barclays | Overweight | $95.00 to $92.00 |
2013-09-18 | Reiterated Rating | Cowen and Company | Hold | $88.00 |
2013-09-18 | Boost Price Target | Goldman Sachs | Buy | $79.00 to $85.00 |
2013-04-19 | Reiterated | Needham | Buy | $65 to $95 |
2013-04-19 | Reiterated | Chardan Capital Markets | Buy | $80 to $105 |
2013-04-10 | Initiated | Chardan Capital Markets | Buy | $80 |
2013-02-07 | Initiated | Robert W. Baird | Outperform | $53 |
2012-11-28 | Downgrade | Argus | Buy to Hold | |
2012-10-04 | Initiated | Argus | Buy | $68 |
2012-06-27 | Initiated | Maxim Group | Buy | $86 |
2012-05-08 | Upgrade | Needham | Hold to Buy | $65 |
2016-07-07 | Reiterated Rating | Maxim Group | Hold | |
2016-06-18 | Reiterated Rating | Piper Jaffray | Buy | |
2016-06-18 | Reiterated Rating | Piper Jaffray Cos. | Buy | |
2016-06-17 | Reiterated Rating | Jefferies Group | Buy | $103.00 |
2016-06-16 | Reiterated Rating | Credit Suisse | Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In VRTX 704 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
BlackRock Inc. | 25.24M |
Vanguard Group, Inc | 21.13M |
FMR LLC | 17.37M |
Capital World Investors | 12.52M |
STATE STREET CORP | 12.29M |
ALLIANCEBERNSTEIN L.P. | 9.15M |
WELLINGTON MANAGEMENT CO LLP | 8.03M |
BlackRock Fund Advisors | 6.82M |
BlackRock Institutional Trust Company, N.A. | 6.53M |
GEODE CAPITAL MANAGEMENT, LLC | 5.27M |
PRICE T ROWE ASSOCIATES INC /MD/ | 5.16M |
JPMORGAN CHASE & CO | 4.86M |
JENNISON ASSOCIATES LLC | 4.76M |
LOOMIS SAYLES & CO L P | 4.16M |
AMERIPRISE FINANCIAL INC | 4.04M |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
BOGER JOSHUA S | 0.12% (284088) | VRTX / |
LEIDEN JEFFREY M CEO & President | 0.08% (190658) | DGX / VRTX / |
MUELLER PETER EVP, Global R&D, CSO | 0.06% (143517) | VRTX / |
Chodakewitz Jeffrey SVP GMDA, CMO | 0.03% (73485) | TTPH / VRTX / |
Horton Kenneth L EVP & Chief Legal Officer | 0.03% (72053) | VRTX / |
ALTSHULER DAVID | 0.03% (69999) | VRTX / |
SMITH IAN F EVP & CFO | 0.03% (64495) | ACOR / INFI / OPHT / VRTX / |
Arbuckle Stuart A EVP\\Chief Commercial Officer | 0.02% (46752) | CERU / VRTX / |
Sachdev Amit SVP, Global Gov. Strategy | 0.02% (46662) | VRTX / |
Pace Megan E SVP, Corp. Communications | 0.02% (43350) | VRTX / |
Parini Michael EVP & CLO | 0.02% (39609) | VRTX / |
Connolly Thomas SVP, Human Resources | 0.01% (34375) | VRTX / |
SACHS BRUCE I | 0.01% (26339) | VRTX / |
Silva Paul M SVP & Corp Controller | 0.01% (16087) | VRTX / |
Graney Thomas Chief Financial Officer | 0.01% (13289) | IRWD / VRTX / |